Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled trial of GS-4875 in moderately to severely active ulcerative colitis
2019-001430-33Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GS-4875 with Placebo (2 arms). Primary endpoint: Clinical remission per Modified Mayo Clinic Score at Week 10. Started Jan 2020; status: completed.
02
Drugs
tilpisertib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-001430-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001430-33.